VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
CLB
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
CLBCore Laboratories N.V.
$10.92$503M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksCLBFinancials

Core Laboratories N.V. (CLB) Financials

30Y historyFree accessUpdated daily

Revenue growth remains inconsistent with a 1.4% year-over-year contraction in 2026Q1, while gross margins have compressed to 16.2% from the 20% levels observed in late 2023.

CLB Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Sales/Revenue524.73M526.52M523.85M509.79M489.74M470.25M487.27M668.21M700.85M659.81M594.74M797.52M1.09B1.07B981.08M907.65M794.65M695.54M780.84M670.54M575.69M483.47M427.43M405.64M364.75M376.57M336.1M303.7M286.2M214.9M105.4M
Revenue Growth %1.34%0.51%2.76%4.1%4.14%-3.49%-27.08%-4.66%6.22%10.94%-25.43%-26.51%1.09%9.42%8.09%14.22%14.25%-10.92%16.45%16.48%19.08%13.11%5.37%11.21%-3.14%12.04%10.67%6.11%33.18%103.89%31.59%
Cost of Goods Sold431.12M432.24M435.48M415.74M410.82M386.41M385.14M495.58M520.05M499.18M469.52M560.11M691.97M688.44M644.74M593.37M513.79M457.77M514.78M449.19M407.1M368.12M336.39M326.92M301.31M293.31M268.65M245.4M220.5M170.5M84.7M
COGS % of Revenue-82.09%83.13%81.55%83.89%82.17%79.04%74.17%74.2%75.66%78.94%70.23%63.76%64.13%65.72%65.37%64.66%65.81%65.93%66.99%70.72%76.14%78.7%80.59%82.61%77.89%79.93%80.8%77.04%79.34%80.36%
Gross Profit93.61M94.28M88.37M94.05M78.92M83.84M102.13M172.63M180.79M160.63M125.22M237.41M393.25M385.07M336.34M314.28M280.86M237.77M266.05M221.35M168.59M115.34M91.03M78.72M63.44M83.26M67.44M58.3M65.7M44.4M20.7M
Gross Margin %17.84%17.91%16.87%18.45%16.11%17.83%20.96%25.83%25.8%24.34%21.06%29.77%36.24%35.87%34.28%34.63%35.34%34.19%34.07%33.01%29.28%23.86%21.3%19.41%17.39%22.11%20.07%19.2%22.96%20.66%19.64%
Gross Profit Growth %-6.69%-6.04%19.17%-5.87%-17.9%-40.84%-4.52%12.55%28.27%-47.25%-39.63%2.13%14.49%7.02%11.9%18.12%-10.63%20.2%31.29%46.16%26.7%15.65%24.08%-23.81%23.46%15.68%-11.26%47.97%114.49%30.19%
Operating Expenses41.06M45.43M29.82M39.41M37.4M38.58M178.93M75.95M62.91M47.74M39.39M49.73M45.66M51.99M43.19M63.52M53.94M50.99M60.19M37.5M45.03M54.41M44.52M45.4M42.68M43.71M32.76M31M24.9M17M8.2M
OpEx % of Revenue-8.63%5.69%7.73%7.64%8.2%36.72%11.37%8.98%7.23%6.62%6.24%4.21%4.84%4.4%7%6.79%7.33%7.71%5.59%7.82%11.25%10.42%11.19%11.7%11.61%9.75%10.21%8.7%7.91%7.78%
Selling, General & Admin46.5M45.43M38.59M38.89M38.12M44.17M32.53M46.52M62.91M47.74M39.39M49.73M45.66M51.99M43.19M41.14M33.03M30.37M31.65M33.84M33.08M37.85M28.14M22.79M20.18M15.93M13.54M12.3M8.4M6M3.6M
SG&A % of Revenue-8.63%7.37%7.63%7.78%9.39%6.68%6.96%8.98%7.23%6.62%6.24%4.21%4.84%4.4%4.53%4.16%4.37%4.05%5.05%5.75%7.83%6.58%5.62%5.53%4.23%4.03%4.05%2.94%2.79%3.42%
Research & Development0000000000000000000000000000000
R&D % of Revenue-------------------------------
Other Operating Expenses-1000K0-8.78M515K-722K-5.59M146.4M29.43M0-452K344K00338K022.38M20.91M20.62M28.54M3.66M11.95M16.57M16.38M22.61M22.5M27.78M19.22M18.7M16.5M11M4.6M
Operating Income52.55M48.85M58.56M54.64M41.52M45.26M-76.81M96.68M118.62M112.44M86.18M161.07M346.53M333.42M297.28M250.75M226.93M186.78M206.71M183.85M123.56M60.93M46.51M33.32M20.76M36.58M34.69M27.3M40.8M27.4M12.5M
Operating Margin %10.01%9.28%11.18%10.72%8.48%9.63%-15.76%14.47%16.93%17.04%14.49%20.2%31.93%31.06%30.3%27.63%28.56%26.85%26.47%27.42%21.46%12.6%10.88%8.21%5.69%9.71%10.32%8.99%14.26%12.75%11.86%
Operating Income Growth %--16.57%7.17%31.59%-8.26%158.93%-179.44%-18.49%5.5%30.47%-46.5%-53.52%3.93%12.16%18.55%10.5%21.49%-9.64%12.44%48.8%102.78%31%39.6%60.51%-43.25%5.45%27.05%-33.09%48.91%119.2%23.76%
EBITDA70.96M63.5M73.51M70.42M58.69M63.78M-55.94M119.29M141.71M136.96M113.05M188.53M373.23M358.89M320.2M274.06M250.19M211.11M228.49M203.32M141.25M77.99M63.91M56.85M40.85M59.11M53.9M46M57.3M38.4M17.1M
EBITDA Margin %13.52%12.06%14.03%13.81%11.98%13.56%-11.48%17.85%20.22%20.76%19.01%23.64%34.39%33.43%32.64%30.19%31.48%30.35%29.26%30.32%24.54%16.13%14.95%14.02%11.2%15.7%16.04%15.15%20.02%17.87%16.22%
EBITDA Growth %2.5%-13.61%4.38%20%-7.99%214.02%-146.89%-15.82%3.46%21.15%-40.03%-49.49%3.99%12.08%16.84%9.54%18.51%-7.61%12.38%43.95%81.11%22.03%12.41%39.16%-30.89%9.66%17.18%-19.72%49.22%124.56%29.55%
D&A (Non-Cash Add-back)18.41M14.65M14.95M15.78M17.16M18.52M20.87M22.61M23.09M24.52M26.87M27.46M26.7M25.47M22.92M23.3M23.27M24.33M21.77M19.48M17.69M17.06M17.4M23.54M20.1M22.54M19.22M18.7M16.5M11M4.6M
EBIT52.55M48.85M58.56M54.64M41.52M45.26M49.63M102.02M118.62M109.97M87.45M161.07M346.53M333.42M297.28M249.74M224.99M186.78M209.88M183.85M123.56M60.93M46.51M35.92M22.98M39.55M34.39M19.04M37.62M30.2M12.5M
Net Interest Income-10.15M-9.86M-12.37M-13.43M-11.57M-9.15M-14.37M-14.69M-13.33M-10.73M-11.57M-12.32M-10.2M-8.54M-8.5M-10.76M-15.59M-15.52M-21.61M000000000000
Interest Income0000000000056K403K776K319K138K249K0848K000000000000
Interest Expense10.15M9.86M12.37M13.43M11.57M9.15M14.37M14.69M13.33M10.73M11.57M12.38M10.6M9.32M8.82M10.9M15.84M15.52M6.43M00007.92M0000000
Other Income/Expense-9.47M-2.96M-12.37M-13.43M-11.57M-9.15M-14.37M-14.69M-13.33M-8.26M-11.57M-12.38M-10.6M-9.32M-8.82M-11.91M-17.78M-15.52M1.55M-2.55M-5.8M-14.29M-8.28M-5.07M-5.38M-7.92M-8.31M-8.56M-3.92M-2.6M-1.3M
Pretax Income43.08M45.9M46.19M41.21M29.95M36.11M-91.18M81.99M105.29M101.71M74.61M148.69M335.93M324.1M288.46M238.84M209.15M171.26M208.6M181.3M117.75M46.64M38.24M25.62M13.15M28.66M27.36M5.1M33.7M22M11.4M
Pretax Margin %8.21%8.72%8.82%8.08%6.12%7.68%-18.71%12.27%15.02%15.41%12.54%18.64%30.95%30.19%29.4%26.31%26.32%24.62%26.72%27.04%20.45%9.65%8.95%6.32%3.61%7.61%8.14%1.68%11.77%10.24%10.82%
Income Tax11.37M13.37M14.03M4.18M10.3M15.89M5.9M-12.29M25.45M18.61M10.75M33.76M77.31M80.91M71.85M54.2M63.75M57.16M65M60.19M35.09M14.93M10.22M6.92M5.53M8.02M8.21M1.7M10.1M6.6M3.7M
Effective Tax Rate %26.4%29.13%30.39%10.16%34.37%44.01%-6.47%-14.99%24.17%18.3%14.41%22.7%23.01%24.96%24.91%22.69%30.48%33.38%31.16%33.2%29.8%32%26.72%27%42%28%30%33.33%29.97%30%32.46%
Net Income31.17M31.8M31.4M36.67M19.45M19.73M-97.64M101.98M79.53M83.13M63.9M114.85M257.49M242.81M216.07M184.68M144.92M113.6M143.6M121.11M82.66M31.21M12.29M18.7M-9.06M20.63M19.15M3.4M20M15.4M7.7M
Net Margin %5.94%6.04%5.99%7.19%3.97%4.2%-20.04%15.26%11.35%12.6%10.74%14.4%23.73%22.62%22.02%20.35%18.24%16.33%18.39%18.06%14.36%6.46%2.88%4.61%-2.48%5.48%5.7%1.12%6.99%7.17%7.31%
Net Income Growth %11.21%1.28%-14.38%88.53%-1.39%120.2%-195.74%28.24%-4.33%30.1%-44.37%-55.4%6.04%12.38%16.99%27.44%27.56%-20.89%18.58%46.51%164.85%153.95%-34.28%306.36%-143.92%7.73%463.29%-83%29.87%100%83.33%
Net Income (Continuing)31.7M32.52M32.15M37.02M19.66M20.16M-97.07M94.28M79.85M80.98M65.02M114.55M258.63M243.02M215.97M184.64M145.4M114.09M131.51M121.11M82.66M31.72M28.02M20.79M9.59M20.63M17.83M2.2M21.19M15.8M6.7M
Discontinued Operations000000-424K7.83M02.11M000000000000000000000
Minority Interest005.75M4.99M4.7M4.55M4.06M4.28M4.14M3.89M3.94M5.37M6.42M6.07M5.68M3.75M2.85M2.39M2.16M1.49M1.45M1.06M1.07M1.07M344K815K1.89M1.3M1.1M1.2M200K
EPS (Diluted)0.680.680.660.770.420.42-2.162.101.791.881.452.685.775.284.543.823.002.432.742.481.540.560.220.30-0.140.300.270.040.290.300.17
EPS Growth %8.93%3.03%-14.29%83.33%0%119.44%-202.86%17.32%-4.79%29.66%-45.9%-53.55%9.28%16.3%18.85%27.33%23.46%-11.31%10.48%61.04%175%154.55%-26.67%314.29%-146.67%11.11%671.43%-87.93%-3.33%76.47%54.55%
EPS (Basic)-0.680.670.790.420.43-2.182.111.801.881.452.715.905.384.663.993.232.472.852.581.650.600.230.31-0.140.310.280.040.300.310.18
Diluted Shares Outstanding46.07M46.5M47.69M47.52M46.81M46.69M44.97M44.65M44.47M44.26M44.15M42.91M44.6M45.99M47.55M48.39M48.24M46.66M47.89M48.82M53.78M56.02M57.52M62.36M66.35M68.54M67.08M64.89M60.5M52M44.71M
Basic Shares Outstanding46.07M46.5M46.9M46.68M46.33M46.01M44.48M44.36M44.21M44.15M43.48M42.38M43.64M45.1M46.35M46.29M44.83M45.94M46.02M47.07M50.31M52.08M53.79M60.42M66.35M66.15M64.78M62.9M58.45M50.32M43.43M
Dividend Payout Ratio-5.88%5.97%5.09%9.53%9.3%-95.68%122.29%116.86%148.91%82.05%34.6%24.15%24.51%24.92%27.46%23.25%19.25%------------

Key Metrics

Growth RegimeMixed
ProfitabilityStrained
Balance SheetHealthy
Cash FlowMixed
Top Statement Risk

Cyclical Revenue Volatility

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Revenue Growth Lacks Consistent Momentum

As reported in recent financial filings, Core Laboratories experienced a 1.4% year-over-year revenue contraction in 2026Q1, highlighting the persistent difficulty in sustaining top-line expansion amidst a volatile energy services environment where quarterly growth rates have fluctuated between a 4.7% decline and a 7.2% increase.

The revenue trajectory appears highly sensitive to the timing of international project cycles and North American completion activity. Investors should monitor whether the recent negative growth in 2026Q1 signals a broader deceleration or merely a temporary lull in project-based revenue recognition.

Structural Margin Pressure Remains Evident

Based on the provided income statement data, Core Laboratories' gross margin reached 16.2% in 2026Q1, reflecting a persistent struggle to maintain profitability levels above the 20% threshold observed in late 2023, suggesting that labor and operational costs continue to weigh heavily on the company's core service offerings.

The compression in gross margins suggests that the company's specialized laboratory services are not immune to inflationary pressures on technical labor. This margin profile warrants further investigation into whether the firm possesses sufficient pricing power to offset rising costs in a competitive global oilfield services market.

Operating Leverage Remains Highly Fragile

According to the latest quarterly data, operating income plummeted to $1.9 million in 2026Q1 from $14.4 million in 2025Q4, demonstrating that the company's high fixed-cost structure prevents meaningful operating leverage when revenue experiences even minor sequential declines, leaving the bottom line vulnerable to operational volatility.

The sharp drop in operating margins from 10.4% to 1.5% in a single quarter indicates that the firm lacks the necessary scale to absorb revenue fluctuations without significant earnings impact. This suggests that management's expense discipline may be insufficient to protect profitability during periods of cyclical demand contraction.

Stock-Based Compensation Distorts Earnings Clarity

As indicated by the reported figures, Core Laboratories recorded $5.0 million in stock-based compensation during 2026Q1, a significant expense that contributed to a net loss of $789,000 and complicates the assessment of true operational profitability when compared to periods with lower or negative stock-based compensation charges.

The volatility in stock-based compensation suggests that reported net income may not accurately reflect the underlying cash-generating capability of the business. Investors should be cautious of these non-cash items, as they appear to mask the true economic cost of retaining the specialized talent required for the firm's operations.

Fragility of the Asset-Light Narrative

While the company is often characterized as asset-light, the income statement data reveals that operating margins are highly sensitive to revenue shifts, suggesting that the firm's reliance on specialized human capital creates a fixed-cost burden that functions similarly to heavy industrial assets during market downturns.

The counter-argument to the bull case is that Core Laboratories cannot easily scale down its laboratory operations without eroding its competitive moat. This implies that the company's earnings quality may be more fragile than the market anticipates, particularly if international offshore demand fails to materialize as expected.

CLB — Frequently Asked Questions

Quick answers to the most common questions about buying CLB stock.

What was Core Laboratories N.V.'s (CLB) revenue in 2025?

For fiscal year 2025, Core Laboratories N.V. (CLB) reported total revenue of $526.5M. This represents a 399.5% increase compared to $105.4M in 1996.

Is Core Laboratories N.V. (CLB) profitable?

Core Laboratories N.V. (CLB) is profitable, generating $31.8M in net income for the fiscal year ending 2025 with a net profit margin of 6.0%.

What is Core Laboratories N.V.'s operating profit margin?

Core Laboratories N.V. (CLB) reported an operating income of $48.9M, resulting in an operating profit margin of 9.3%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Core Laboratories N.V.'s gross profit and gross margin?

Core Laboratories N.V. (CLB) generated $94.3M in gross profit for the year, representing a gross profit margin of 17.9%. This demonstrates the company's core pricing power and production efficiency.